Literature DB >> 26977282

Gout: optimizing treatment to achieve a disease cure.

José Antonio Bernal1, Neus Quilis2, Mariano Andrés2, Francisca Sivera3, Eliseo Pascual4.   

Abstract

Gout is one of the most common inflammatory arthritides. The disease is due to the deposition of monosodium urate crystals. These deposits are reversible with proper treatment, suggesting that gout is a curable disease. The main aim in gout is to lower serum uric acid levels to a pre-established target; there are different urate-lowering drugs (xanthine oxidase inhibitors, uricosurics and uricases) through which this can be achieved. Proper treatment of gout also involves correct management of acute flares and their prevention. To ensure treatment adherence it is necessary to explain to the patient what the objectives are.

Entities:  

Keywords:  allopurinol; colchicine; gout; monosodium urate crystals; uric acid

Year:  2016        PMID: 26977282      PMCID: PMC4772341          DOI: 10.1177/2040622315618393

Source DB:  PubMed          Journal:  Ther Adv Chronic Dis        ISSN: 2040-6223            Impact factor:   5.091


  78 in total

1.  Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment.

Authors:  Michael D Mayer; Reza Khosravan; Laurent Vernillet; Jing-Tao Wu; Nancy Joseph-Ridge; Darcy J Mulford
Journal:  Am J Ther       Date:  2005 Jan-Feb       Impact factor: 2.688

2.  Benzbromarone withdrawn from the European market: another case of "absence of evidence is evidence of absence"?

Authors:  T L Th A Jansen; M K Reinders; E N van Roon; J R B J Brouwers
Journal:  Clin Exp Rheumatol       Date:  2004 Sep-Oct       Impact factor: 4.473

3.  Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol.

Authors:  M K Reinders; E N van Roon; T L Th A Jansen; J Delsing; E N Griep; M Hoekstra; M A F J van de Laar; J R B J Brouwers
Journal:  Ann Rheum Dis       Date:  2008-02-04       Impact factor: 19.103

Review 4.  Efficacy and safety of etoricoxib compared with NSAIDs in acute gout: a systematic review and a meta-analysis.

Authors:  Shaobo Zhang; Yibao Zhang; Peng Liu; Wei Zhang; Jing-Lin Ma; Jing Wang
Journal:  Clin Rheumatol       Date:  2015-06-24       Impact factor: 2.980

5.  Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis.

Authors:  Gregory C Borstad; Leslie R Bryant; Michael P Abel; Daren A Scroggie; Mark D Harris; Jeff A Alloway
Journal:  J Rheumatol       Date:  2004-12       Impact factor: 4.666

6.  Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout.

Authors:  Fernando Perez-Ruiz; Marcelo Calabozo; Jose I Pijoan; Ana M Herrero-Beites; Ana Ruibal
Journal:  Arthritis Rheum       Date:  2002-08

7.  Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency.

Authors:  K R Hande; R M Noone; W J Stone
Journal:  Am J Med       Date:  1984-01       Impact factor: 4.965

Review 8.  A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients?

Authors:  Ming-Han H Lee; Garry G Graham; Kenneth M Williams; Richard O Day
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

Review 9.  Recent developments in diet and gout.

Authors:  Susan J Lee; Robert A Terkeltaub; Arthur Kavanaugh
Journal:  Curr Opin Rheumatol       Date:  2006-03       Impact factor: 5.006

10.  Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study.

Authors:  E W Campion; R J Glynn; L O DeLabry
Journal:  Am J Med       Date:  1987-03       Impact factor: 4.965

View more
  6 in total

Review 1.  Review: Gout: A Roadmap to Approaches for Improving Global Outcomes.

Authors:  Nicola Dalbeth; Hyon K Choi; Robert Terkeltaub
Journal:  Arthritis Rheumatol       Date:  2017-01       Impact factor: 10.995

2.  Systematic Structure-Activity Relationship (SAR) Exploration of Diarylmethane Backbone and Discovery of A Highly Potent Novel Uric Acid Transporter 1 (URAT1) Inhibitor.

Authors:  Wenqing Cai; Jingwei Wu; Wei Liu; Yafei Xie; Yuqiang Liu; Shuo Zhang; Weiren Xu; Lida Tang; Jianwu Wang; Guilong Zhao
Journal:  Molecules       Date:  2018-01-27       Impact factor: 4.411

3.  Incident gout and weight change patterns: a retrospective cohort study of US adults.

Authors:  Lu Bai; Jian-Bo Zhou; Tao Zhou; Roger B Newson; Marly Augusto Cardoso
Journal:  Arthritis Res Ther       Date:  2021-03-02       Impact factor: 5.156

4.  The Effect of Low and Moderate Exercise on Hyperuricemia: Protocol for a Randomized Controlled Study.

Authors:  Yuning Hou; Renyan Ma; Song Gao; Keneilwe Kenny Kaudimba; Hongmei Yan; Tiemin Liu; Ru Wang
Journal:  Front Endocrinol (Lausanne)       Date:  2021-09-02       Impact factor: 5.555

5.  Identification of xanthine oxidase inhibitors through hierarchical virtual screening.

Authors:  Ying Yang; Lei Zhang; Jinying Tian; Fei Ye; Zhiyan Xiao
Journal:  RSC Adv       Date:  2020-07-24       Impact factor: 4.036

Review 6.  Weight loss for overweight and obese individuals with gout: a systematic review of longitudinal studies.

Authors:  Sabrina M Nielsen; Else M Bartels; Marius Henriksen; Eva E Wæhrens; Henrik Gudbergsen; Henning Bliddal; Arne Astrup; Filip K Knop; Loreto Carmona; William J Taylor; Jasvinder A Singh; Fernando Perez-Ruiz; Lars E Kristensen; Robin Christensen
Journal:  Ann Rheum Dis       Date:  2017-09-02       Impact factor: 19.103

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.